Measurement of Biochemical Markers of Bone Formation

Dynamics of Bone and Cartilage Metabolism

Volumn , Issue , 2006, Pages 529-540

  Naylor, Kim E ^a   Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79952780465     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012088562-6/50033-9     Document Type: Chapter

References (104)

1. Owen T.A., Aronow M., Shalhoub V., Barone L.M., Wilming L., Tassinari M.S., Kennedy M.B., Pockwinse S., Lian J.B., Stein G.S. Progressive development of the rat osteoblast phenotype in vitro: reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J. Cell. Physiol. 1990, 143:420-430.
2. Siggelkow H., Rebenstorff K., Kurre W., Niedhart C., Engel I., Schulz H., Atkinson M.J., Hufner M. Development of the osteoblast phenotype in primary human osteoblasts in culture: comparison with rat calvarial cells in osteoblast differentiation. J. Cell. Biochem. 1999, 75:22-35.
3. Stein G.S., Lian J.B., Stein J.L., Van Wijnen A.J., Montecino M. Transcriptional control of osteoblast growth and differentiation. Physiol. Rev. 1996, 76:593-629.
4. Owen T.A., Aronow M.S., Barone L.M., Bettencourt B., Stein G.S., Lian J.B. Pleiotropic effects of vitamin D on osteoblast gene expression are related to the proliferative and differentiated state of the bone cell phenotype: dependency upon basal levels of gene expression, duration of exposure, and bone matrix competency in normal rat osteoblast cultures. Endocrinology 1991, 128:1496-1504.
5. Eastell R., Robins S.P., Colwell T., Assiri A.M., Riggs B.L., Russell R.G. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos. Int. 1993, 3:255-260.
6. Smedsrod B., Melkko J., Risteli L., Risteli J. Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 1990, 271:345-350.
7. 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J. Exp. Med. 1994, 179:405-412.
8. Heikkinen J., Rutanen E.M., Halonen K., Lammintausta R., Ylikorkala O. Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. Gynecol. Endocrinol. 2004, 18:152-158.
9. Guanabens N., Pares A., Alvarez L., Martinez de Osaba M.J., Monegal A., Peris P., Ballesta A.M., Rodes J. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 1998, 13:731-738.
10. Parfitt A.M., Simon L.S., Villanueva A.R., Krane S.M. Procollagen type 1 carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone. Correlation with Iliac bone formation rates and comparison with total alkaline phosphatase. J. Bone Miner. Res. 1987, 2:427-436.
11. Dominguez C.C., Sosa H.M., Traba M.L., Alvarez V.E., de la Piedra C. Biochemical markers of bone formation in the study of postmenopausal osteoporosis. Osteoporos. Int. 1998, 8:147-151.
12. Orum O., Hansen M., Jensen C.H., Sorensen H.A., Jensen L.B., Horslev-Petersen K., Teisner B. Procollagen type I N-terminal propeptide (PINP) as an indicator of type I collagen metabolism: ELISA development, reference interval, and hypovitaminosis D induced hyperparathyroidism. Bone 1996, 19:157-163.
13. Jensen C.H., Hansen M., Brandt J., Rasmussen H.B., Jensen P.B., Teisner B. Quantification of the N-terminal propeptide of human procollagen type I (PINP): comparison of ELISA and RIA with respect to different molecular forms. Clinica. Chimica. Acta. 1998, 269:31-41.
14. Brandt J., Krogh T.N., Jensen C.H., Frederiksen J.K., Teisner B. Thermal instability of the trimeric structure of the N-terminal propeptide of human procollagen type I in relation to assay technology. Clin. Chem. 1998, 41:47-53.
15. Woitge H.W., Scheidt-Nave C., Kissling C., Leidig-Bruckner G., Meyer K., Grauer A., Scharla S.H., Ziegler R., Seibel M.J. Seasonal variation of biochemical indexes of bone turnover: results of a population-based study. J. Clin. Endocrinol. Metab. 1998, 83:68-75.
16. Blumsohn A., Naylor K.E., Timm W., Eagleton A.C., Hannon R.A., Eastell R. Absence of marked seasonal change in bone turnover: a longitudinal and multicenter cross-sectional study. J. Bone Miner. Res. 2003, 18:1274-1281.
17. Brahm H., Strom H., Piehl-Aulin K., Mallmin H., Ljunghall S. Bone metabolism in endurance trained athletes: a comparison to population-based controls based on DXA, SXA, quantitative ultrasound, and biochemical markers. Calcif. Tissue. Int. 1997, 61:448-454.
18. Bennell K.L., Malcolm S.A., Khan K.M., Thomas S.A., Reid S.J., Brukner P.D., Ebeling P.R., Wark J.D. Bone mass and bone turnover in power athletes, endurance athletes, and controls: a 12-month longitudinal study. Bone 1997, 20:477-484.
19. Blumsohn A., Hannon R.A., Wrate R., Barton J., Al-Dehaimi A.W., Colwell A., Eastell R. Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. 1994, 40:663-670.
20. Joerring S., Jensen L.T., Anderson G.R., Johansen J.S. Types I and III procollagen extension peptides in serum respond to fracture in human. Arch. Orthop. Trauma Surg. 1992, 111:265-267.
21. Ingle B.M., Hay S.M., Bottjer H.M., Eastell R. Changes in bone mass and bone turnover following ankle fracture. Osteoporos. Int. 1999, 10:408-415.
22. Ingle B.M., Hay S.M., Bottjer H.M., Eastell R. Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos. Int. 1999, 10:399-407.
23. Hernandez M.V., Guanabens N., Alvarez L., Monegal A., Peris P., Riba J., Ercilla G., Martinez de Osaba M.J., Munoz-Gomez J. Immunocytochemical evidence on the effects of glucocorticoids on type I collagen synthesis in human osteoblastic cells. Calcif. Tissue. Int. 2004, 74:284-293.
24. Cooper M.S., Blumsohn A., Goddard P.E., Bartlett W.A., Shackleton C.H., Eastell R., Hewison M., Stewart P.M. 11 beta-hydroxysteroid dehydrogenase type 1 activity predicts the effects of glucocorticoids on bone. J. Clin. Endocrinol. Metab. 2003, 88:3874-3877.
25. Winterbottom N., Vernon S., Freeman K., Daniloff G., Seyedin S. A serum immunoassay for the C-terminal propeptide of type 1 collagen. J. Bone Miner. Res. 1993, 8:S341.
26. Reid I.R., Davison J.S., Wattie D., Wu F., Lucas J., Gamble G.D., Rutland M.D., Cundy T. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget's disease of bone. Bone 2004, 35:224-230.
27. Alvarez L., Guanabens N., Peris P., Vidal S., Ros I., Monegal A., Bedini J.L., Deulofeu R., Pons F., Munoz-Gomez J., Ballesta A.M. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001, 29:447-452.
28. Suvanto-Luukkonen E., Risteli L., Sundstrom H., Penittinen J., Kauppila A., Risteli J. Comparison of three serum assays for bone collagen formation during postmeno pausal estrogen-progestin therapy. Clinica. Chimica. Acta. 1997, 266:105-116.
29. Peris P., Alvarez L., Monegal A., Guanabens N., Duran M., Pons F., Martinez de Osaba M.J., Echevarria M., Ballesta A.M., Munoz-Gomez J. Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 1999, 25:349-353.
30. Naylor K.E., Iqbal P., Fledelius C., Fraser R., Eastell R. The effect of pregnancy on bone density and bone turnover. J. Bone Miner. Res. 2000, 15:129-137.
31. Alvarez L., Torregrosa J.V., Peris P., Monegal A., Bedini J.L., Martinez de Osaba M.J., Filella X., Martin G., Ricos C., Oppenheimer F., Ballesta A.M. Effect of hemodialysis and renal failure on serum biochemical markers of bone turnover. J. Bone Miner. Metab. 2004, 22:254-259.
32. Tsuchida T., Ishimura E., Miki T., Matsumoto N., Naka H., Jono S., Inaba M., Nishizawa Y. The clinical significance of serum osteocalcin and N-terminal propeptide of type I collagen in predialysis patients with chronic renal failure. Osteoporos. Int. 2005, 16:172-179.
33. de la Piedra C., Castro-Errecaborde N.A., Traba M.L., Mendez-Davila C., Garcia-Moreno C., Rodriguez D.A., Rodriguez-Molina J. Bone remodeling markers in the detection of bone metastases in prostate cancer. Clin. Chim. Acta. 2003, 331:45-53.
34. Jung K., Lein M., Stephan C., Von Hosslin K., Semjonow A., Sinha P., Loening S.A., Schnorr D. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications. Int. J. Cancer 2004, 111:783-791.
35. Simojoki M., Santala M., Risteli J., Kauppila A. Discrepant expression of carboxy- and aminoterminal propertides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer. Gynecol. Oncol. 2003, 88:358-362.
36. 47Ca-kinetics. Efficiency of serum bone gamma-carboxyglutamic acid-containing protein, serum alkaline phosphatase, and urinary hydroxyproline excretion. J. Clin. Invest. 1985, 76:2254-2258.
37. Delmas P.D. Biochemical markers of bone turnover in osteoporosis. Osteoporosis 1988, 297-316. Raven Press, New York. B.L. Riggs, L.J. Melton (Eds.).
38. Fishman W.H. Alkaline phosphatase isoenzymes: recent progress. Clin. Biochem. 1990, 23:99-104.
39. Van Hoof V.O., De Broe M.E. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit. Rev. Clin. Lab. Sci. 1994, 31:197-293.
40. Moss D.W., Whitby L.G. A simplified heat-inactivation method for investigating alkaline phosphatase isoenzyme in serum. Clin. Chim. Acta. 1975, 61:63-71.
41. Calvo M.S., Eyre D.R., Gundberg C.M. Molecular basis and clinical application of biological markers of bone turnover. Endocrine Rev. 1996, 17:333-368.
42. Lawson G.M., Katzman J.A., Kimlinger T.K., O'Brien J.F. Isolation and preliminary characterization of a monoclonal antibody that interacts preferentially with the liver isoenzyme of human alkaline phosphatase. Clin. Chem. 1985, 31:381-385.
43. Garnero P., Delmas P.D. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 1993, 77:1046-1053.
44. Gomez B.J., Ardakani S., Ju J., Jenkins D., Cerelli M.J., Daniloff G.Y., Kung V.T. Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin. Chem. 1995, 41:1560-1566.
45. Hata K., Tokuhiro H., Nakatsuka K., Miki T., Nishizawa Y., Morii H., Miura M. Measurement of bone-specific alkaline phosphatase by an immunoselective enzyme assay method. Ann. Clin. Biochem. 1996, 33:127-131.
46. Hill C.S., Wolfert R.L. The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatases. Clin. Chim. Acta. 1989, 186:315-320.
47. Crofton P.M. Biochemistry of the alkaline phosphatase isoenzymes. Crit. Rev. Clin. Lab. Sci. 1982, 16:161-194.
48. Nielsen H.K., Brixen K., Bouillon R., Mosekilde L. Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J. Clin. Endocrinol. Metab. 1990, 70:1431-1437.
49. Greenspan S.L., Dresner-Pollak R., Parker R.A., London D., Ferguson L. Diurnal variation of bone mineral turnover in elderly men and women. Calcif. Tissue Int. 1997, 60:419-423.
50. Devgun M.S., Paterson C.R., Martin B.T. Seasonal changes in the activity of serum alkaline phosphatase. Enzyme 1981, 26:301-305.
51. Douglas A.S., Miller M.H., Reid D.M., Hutchison J.D., Porter R.W., Robins S.P. Seasonal differences in biochemical parameters of bone remodelling. J. Clin. Pathol. 1996, 49:284-289.
52. Hannon R., Eastell R. Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 2000, II(Suppl 6):S30-S44.
53. Crofton P.M. Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children: age-dependent reference ranges and changes in liver and bone disease. Clin. Chem. 1992, 38:663-670.
54. Cross N.A., Hillman L.S., Allen S.H., Krause G.F., Vieira N.E. Calcium homeostasis and bone metabolism during pregnancy, lactation and postweaning: a longitudinal study. Am. J. Clin. Nutr. 1995, 61:514-523.
55. Black A.J., Topping J., Durham B., Farquharson R.G., Fraser W.D. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J. Bone Miner. Res. 2000, 15:557-563.
56. Bowles S.A., Kurdy N., Davis A.M., France M.W., Marsh D.R. Serum osteocalcin, total and bone specific alkaline phosphatase following isolated tibial shaft fracture. Ann. Clin. Biochem. 1996, 33:196-200.
57. Bowles S.A., Kurdy N., Davis A.M., France M.W. Changes in serum bone-specific alkaline phosphatase following tibial fracture. Ann. Clin. Biochem. 1997, 34:690-691.
58. Woitge H.W., Seibel M.J., Ziegler R. Comparison of total and bone specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone disease. Clin. Chem. 1996, 42:1796-1804.
59. Kress B.C., Mizrahi I.A., Armour K.W., Marcus R., Emkey R.D., Santora A.C. Use of bone alkaline phosphatase to monitor a lendronate therapy in individual postmenopausal osteoporotic women. Clin. Chem. 1999, 45:1009-1017.
60. Braga de Castro M.A., Hannon R., Eastell R. Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 1999, 14:602-608.
61. Rogers A., Saleh G., Hannon R.A., Greenfield D., Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J. Clin. Endocrinol. Metab. 2002, 87:4470-4475.
62. Eastell R., Hannon R.A., Cuzick J., Clack G., Adams J.E. Effect of anastrozole on bone density and bone turnover: Results of the 'Arimidex' (Anastrozole), Tamoxifen, Alone or in Combination (ATAC) Study. J. Bone Miner. Res. 2002, 17:S165.
63. Woitge H.W., Horn E., Keck A.V., Auler B., Seibel M.J., Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin. Chem. 2001, 47:686-693.
64. Abildgaard N., Brixen K., Eriksen E.F., Kristensen J.E., Nielsen J.L., Heickendorff L. Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma. Haematologica 2004, 89:567-577.
65. Lee A.J., Hodges S., Eastell R. Measurement of osteocalcin. Ann. Clin. Biochem. 2000, 37(Pt 4):432-446.
66. Taylor A.K., Linkhart S., Mohan S., Chrinstenson R.A., Singer F.R., Baylink D. Multiple osteocalcin fragments in human urine and serum as detected by a midmolecule osteocalcin radioimmunoassay. J. Clin. Endocrinol. Metab. 1990, 70:467-472.
67. Gundberg C., Weinstein R.S. Multiple immunoreactive forms in uremic serum. J. Clin. Invest. 1986, 77:1762-1767.
68. Gamero P., Grimaux M., Seguin P., Delmas P.D. Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J. Bone Miner. Res. 1994, 9:255-264.
69. Merle B., Delmas P.D. Normal carboxylation of circulating osteocalcin (bone Gla protein) in Paget's disease of bone. Bone Miner. 1990, 11:237-245.
70. Vergnaud P., Garnero P., Meunier P.J., Breart G., Kamihagi K., Delmas P.D. Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women: the EPIDOS study. J. Clin. Endocrinol. Metab. 1997, 82:719-724.
71. Power M.J., Fottrell P.F. Osteocalcin: diagnostic methods and clinical applications. Crit. Rev. Clin. Lab. Sci. 1991, 28:287-335.
72. Szule P., Arlot M., Chapuy M.-C., Duboeuf F., Meunier P.J., Delmas P.D. Serum undercarboxylated osteocalcin correlates with hip bone mineral density in elderly women. J. Bone Miner. Res. 1994, 9:1591-1595.
73. Rosenquist C., Qvist P., Bjarnason N., Christiansen C. Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin. Chem. 1995, 41:1439-1445.
74. Colford J., Sailer D., Langman C. Five osteocalcin assays compared: tracer specificity, fragment interference, and calibration. Clin. Chem. 1997, 43:1240-1241.
75. Souberbielle J.C., Marque D., Bonnet P., Herviaux P., Sachs C. Simple method to evaluate specificity of osteocalcin immunoassays. Clin. Chem. 1997, 43:1663-1664.
76. Eastell R., Delmas P.D., Hodgson S.F., Eriksen E.P., Mann K.G. Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J. Clin. Endocrinol. Metab. 1988, 67:741-748.
77. Brown J.P., Delmas P.D., Malaval L., Edouard C., Chapuy M.C., Meunier P.J. Serum bone Gla-protein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984, 1:1091-1093.
78. Diego E.M.D., Guerrero R., de la Piedra C. Six osteocalcin assays compared. Clin. Chem. 1994, 40:2071-2077.
79. Garnero P., Grimaux M., Demiaux B., Preaudat C., Seguin P., Delmas P.D. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J. Bone Miner. Res. 1992, 7:1389-1398.
80. Taylor A.K., Linkhart S.G., Mohan S., Baylink D.J. Development of a new radioimmunoassay for human osteocalcin: evidence for a mid molecule epitope. Metabolism 1988, 37:872-877.
81. Masters P.W., Jones R.G., Purves D.A., Cooper E.H., Cooney J.M. Commercial assays for serum osteocalcin give clinically discordant results. Clin. Chem. 1994, 40:358-363.
82. Tracy R.P., Andrianorivo A., Riggs B.L., Mann K.G. Comparison of monoclonal and polyclonal antibody-based immunoassays for osteocalcin: a study of sources of variation in assay results. J. Bone. Miner. Res. 1990, 5:451-461.
83. Power M.J., O'Dwyer B., Breen E., Fottrell P.F. Osteocalcin concentrations in plasma prepared with different anticoagulants. Clin. Chem. 1991, 37:281-284.
84. Blumsohn A., Hannon R.A., Eastell R. Apparent instability of osteocalcin in serum as measured with different commercially available immunoassays. Clin. Chem. 1995, 41:318-319.
85. Eastell R., Calvo M.S., Burritt M.F., Offord K.P., Russell R.G.G., Riggs B.L. Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J. Clin. Endocrinol. Metab. 1992, 74:487-494.
86. Nielsen H.K., Brixen K., Kassem M., Charles P., Mosekilde L. Inhibition of the morning cortisol peak abolishes the expected morning decrease in serum osteocalcin in normal males: evidence of a controlling effect of serum cortisol on the circadian rhythm in serum osteocalcin. J. Clin. Endocrinol. Metab. 1992, 74:1410-1414.
87. Thomsen K., Eriksen E.F., Jorgensen J.C., Charles P., Mosekilde L. Seasonal variation of bone-Gla protein. Scand. J. Clin. Lab. Invest. 1989, 49:605-611.
88. Vanderschueren D., Gevers G., Raymaekers G., Devos P., Dequeker J. Sex and age-related changes in bone and serum osteocalcin. Calcif. Tissue. Int. 1990, 46:179-182.
89. Obrant K.J., Merle B., Bejui J., Delmas P.D. Serum bone-gla protein after fracture. Clin. Orthop. 1990, 258:300-303.
90. Rodin A., Duncan A., Quartero H.W.P., Pistofidis G., Mashiter G., Whitaker K., Crook D., Stevenson J.C., Chapman M.G., Fogelman I. Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J. Clin. Endocrinol. Metab. 1989, 68:1123-1127.
91. Godschalk M.F., Downs R.W. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J. Bone Miner. Res. 1988, 3:113-115.
92. Heuck C., Wolthers O.D. A placebo-controlled study of three osteocalcin assays for assessment of prednisolone-induced suppression of bone turnover. J. Endocrinol. 1998, 159:127-131.
93. Garnero P., Shih W.J., Gineyts E., Karpf D.B., Delmas P.D. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 1994, 79:1693-1700.
94. Delmas P.D., Demiaux B., Malaval L., Chapuy M.-C., Meunier P.J. Serum bone GLA-protein is not a sensitive marker of bone turnover in Paget's disease of bone. Calcif. Tiss. Int. 1986, 38:60-61.
95. Ingram R.T., Park Y.K., Clarke B.L., Fitzpatrick L.A. Age- and gender-related changes in the distribution of osteocalcin in the extracellular matrix of normal male and female bone. Possible involvement of osteocalcin in bone remodeling. J. Clin. Invest. 1994, 93:989-997.
96. Alvarez L., Peris P., Guanabens N., Vidal S., Quinto L., Monegal A., Pons F., Ballesta A.M., Munoz-Gomez J. Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment. Rheumatology (Oxford) 2004, 43:869-874.
97. Hannon R.A., Blumsohn A., Naylor K.E., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therpay: impact of biological variability. J. Bone Miner. Res. 1998, 13:1124-1133.
98. Riggs B.L. Are biochemical markers for bone turnover clinically useful for monitoring therapy in individual osteoporotic patients. Bone 2000, 26:551-552.
99. Alvarez L., Ricos C., Peris P., Guanabens N., Monegal A., Pons F., Ballesta A.M. Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 2000, 26:571-576.
100. Bernardi D., Zaminotto M., Plebani M. Requirements for improving quality in the measurement of bone markers. Clin. Chim. Acta. 2004, 346:79-86.
101. Mundy G., Garrett R., Harris S., Chan J., Chen D., Rossini G., Boyce B., Zhao M., Gutierrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
102. Clowes J.A., Hannon R.A., Yap T.S., Hoyle N.R., Blumsohn A., Eastell R. Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 2002, 30:886-890.
103. Schmidt-Gayk H., Spanuth E., Kotting J., Bartl R., Felsenberg D., Pfeilschifter J., Raue F., Roth H.J. Performance evaluation of automated assays for beta-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin. Chem. Lab. Med. 2004, 42:90-95.
104. Seibel M.J., Lang M., Geilenkeuser W.J. Interlaboratory variation of biochemical markers of bone turnover. Clin. Chem. 2001, 47:1443-1450.